Abbott Laboratories vs. Lantern Pharma Inc. Common Stock
Abbott Laboratories and Lantern Pharma Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | LTRN | |
|---|---|---|
| Market Cap | $173.21 billion | $12.85 million |
| Revenue (TTM) | — | — |
| Net Income (TTM) | — | $-18,652,935 |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | LTRN | |
|---|---|---|
| Price / Book | — | -3.99 |
ABT and LTRN split the valuation factors evenly.
Profitability
| ABT | LTRN | |
|---|---|---|
| Return on Equity | — | 579.78% |
ABT and LTRN split the profitability factors evenly.
Dividend
| ABT | LTRN | |
|---|---|---|
| Dividend Yield | 2.57% | — |
ABT and LTRN split the dividend factors evenly.
Risk & Sentiment
| ABT | LTRN | |
|---|---|---|
| Short Interest | 0.57% | 0.21% |
LTRN leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, LTRN overview, LTRN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.